Antihyperglycaemic effect of Cardiospermum halicacabum Linn. leaf extract on STZ-induced diabetic rats

Abstract

The present study was designed to investigate the antihyperglycaemic effect of ethanolic extract of Cardiospermum halicacabum Linn. (Sapindaceae) leaves on normal and streptozotocin (STZ) diabetic rats. Diabetes was induced into male albino Wistar rats by intraperitonial administration of STZ. The Cardiospermum halicacabum leaf extract (CHE) was administered orally at three different doses to normal and STZ-diabetic rats for 45 days. The diabetic rats showed an increase in levels of blood glucose and glycosylated haemoglobin (HbA 1c) and a decrease in the levels of insulin and haemoglobin (Hb). In addition, diabetic rats showed a significant reduction in the activity of glucokinase and an elevation in the activities of gluconeogenic enzymes such as glucose-6-phosphatase and fructose-1, 6-bisphosphatase. Treatment with CHE significantly decreased plasma glucose and HbA 1c , and increased the levels of insulin and Hb. CHE administration to diabetic rats reversed these enzyme activities in a significant manner. Thus, the results show that CHE possesses an antihyperglycaemic activity and provide evidence for its traditional usage in the control of diabetes. The 200 mg dose of the extract produced a better effect than 50 or 100 mg doses.

Investigation of Antidiabetic, Antihyperlipidemic, and In Vivo Antioxidant Properties of Sphaeranthus indicus Linn. in Type 1 Diabetic Rats: An Identification of Possible Biomarkers

“…The loss of body weight after administration of STZ may be due to the loss of degradation of structural proteins [32]. The administration of EESIR improves body weight compared to diabetic rats and it indicates preventive effect of EESIR on degradation of structural proteins.…”

Antidiabetic and antioxidative efficacy of the constituents present in the fraction solvents of Curcuma amada rhizomes: An experimental study on the diabetic rat model

“…Diabetes mellitus (DM) is a cluster form of diseases symbolized by abnormal high blood sugar and an elevated risk of complications from vascular diseases (Davis & Granner, ). The metabolic and endocrine disorders take place due to impaired insulin action and or secretion (Veeramani, Pushpavalli, & Pugalendi, ). Currently, there are 382 million people affected by diabetes worldwide and assumed to increase to 592 million by the year 2035 (Gandhi & Wareham, ).…”

Chitosan–zinc–insulin complex incorporated thermosensitive polymer for controlled delivery of basal insulin in vivo

“…No signs of retinopathy were observed in rats treated with zinc-insulin or chitosan-zinc-insulin containing formulations indicated that the released insulin helped in preventing the onset of diabetes related microvascular complications. It has been reported that STZ induced diabetes causes reduction in body weight due to the loss/degradation of structural proteins, which mainly contribute to the body weight [47]. Thus, after STZ treatment, a significant and drastic weight loss was observed in all groups.…”